ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Tuesday, 17 November 2026 NSE & BSE filings, as they land
ALFA News Straight from the exchange filing
Partnership

AstraZeneca Pharma India Signs Healthcare Collaboration LOI with Strand Life Sciences

AstraZeneca Pharma India Limited has signed a Letter of Intent with Strand Life Sciences Private Limited to explore collaborative opportunities in the Indian healthcare sector. Strand Life Sciences, a specialist in genomics research and diagnostics, is a subsidiary of Reliance Industries Limited.

Spacious laboratory interior featuring state-of-the-art machines and computers for research purposes. Stock photo illustrating AstraZeneca Pharma India's partnership story.
Photo: Tima Miroshnichenko / Pexels
Key numbers
Market Cap ₹15,260 CrPharmaceuticals
Quarterly Revenue ₹729.1 Cr30.4% YoY Growth
P/E TTM 85.86Sector PE 43.58
1-Year Return -33.31%Price Performance

Key highlights

  • Strategic Letter of Intent signed with Strand Life Sciences Private Limited
  • Partner is a genomics research subsidiary of Reliance Industries Limited
  • Collaboration aims to explore new healthcare delivery opportunities across India
  • Company reported a 30.41% YoY increase in quarterly revenue to ₹729.1 Crore
  • AstraZeneca confirmed the parties are not related and the LOI involves no related party transaction

A Strategic Alliance with Strand Life Sciences

AstraZeneca Pharma India has entered into a non-binding agreement with Strand Life Sciences Private Limited, a genomics research and diagnostics firm. Strand operates as a subsidiary of Reliance Industries Limited, marking a notable tie-up between the global pharmaceutical major's Indian arm and one of the country's largest conglomerate-backed diagnostic entities. The collaboration is designed to explore various opportunities within the Indian healthcare landscape, leveraging Strand's expertise in genomics to potentially enhance AstraZeneca's diagnostic and therapeutic reach in the region.

The execution of this Letter of Intent does not constitute a related party transaction.

Financial Performance and Valuation Context

The partnership announcement comes on the heels of strong quarterly results for the period ended September 30, 2026. AstraZeneca Pharma India reported an operating revenue of ₹729.1 Crore, representing a 30.41% growth compared to the same quarter last year. Net profit for the quarter stood at ₹62.33 Crore, surging 64.33% on a sequential basis.

While the company maintains a robust net profit TTM of ₹177.73 Crore, its valuation remains high with a P/E ratio of 85.86, nearly double the sector average of 43.58. The stock has faced pressure over the last year, declining 33.31% from its high.

AstraZeneca Pharma India · share price, past month

Expanding the Indian Healthcare Ecosystem

  • November 07, 2026: Confirmed rollout of breast cancer drug Datverzo in the Indian market
  • October 14, 2026: Partnered with NIPER Raebareli to build clinical research capabilities at 25 sites
  • July 28, 2026: Signed MoU with Andhra Pradesh for an Integrated Genomic Solutions Centre
  • April 07, 2026: Collaborated with Telangana for AI-enabled lung cancer screening in 20 facilities
  • November 17, 2025: Entered a ₹26.00 Crore distribution agreement with Sun Pharma for Lokelma

Official Disclosure on Collaboration

This is to inform that AstraZeneca Pharma India Limited has signed a Letter of Intent with Strand Life Sciences Private Limited, a genomics research and diagnostics company and a subsidiary of Reliance Industries Limited, to explore opportunities to collaborate in healthcare in India.

— Tanya Sanish, Company Secretary & Compliance Officer, AstraZeneca Pharma India
Earlier announcements by AstraZeneca Pharma India
DateAnnouncementAmount
14 Oct 2026Partnership with NIPER Raebareli to build clinical research capabilities across 25 emerging clinical trial sites under Biopharma SHAKTISource: ddnews.gov.in–
28 Jul 2026MoU with the Government of Andhra Pradesh to establish an Integrated Genomic Solutions Centre and precision oncology ecosystem in AmaravatiSource: thehindu.com–
07 Apr 2026MoU with the Government of Telangana to deploy AI-enabled lung cancer screening across 20 public healthcare facilitiesSource: astrazeneca.in–
17 Nov 2025Distribution services agreement and second brand partnership with Sun Pharma for Sodium Zirconium Cyclosilicate (Lokelma/Gimliand)Source: sunpharma.com₹26.00 Cr

What to watch next

  • Commercial rollout of breast cancer drug Datverzo scheduled for late November 2026
  • Updates on the Integrated Genomic Solutions Centre project in Andhra Pradesh
  • Expansion of clinical research capabilities across the 25 NIPER-affiliated sites
  • Next quarterly financial results expected in February 2027
AstraZeneca Pharma India · financial snapshot
Share price₹6104
Market capitalisation₹15,260.00 Cr
Revenue (annual)₹2,275.58 Cr
Net profit (annual)₹187.52 Cr
Revenue (latest quarter)₹729.10 Cr+6.78% vs previous quarter
Net profit (latest quarter)₹62.33 Cr+64.33% vs previous quarter
P/E (TTM)85.86×Sector 43.58×
Promoter holding75%0.00% QoQ
FII holding2.64%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Exchange filing by AstraZeneca Pharma India Limited announcing a Letter of Intent with Strand Life Sciences. Market figures from a third-party data provider.

Read the filing ↗
Every AstraZeneca Pharma India announcement on ALFA FilingsSee filings →

More in Partnerships

All →